NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Presentation
Phase 1 Dose-Escalation Study of STRO-002, an Anti-Folate-Receptor Alpha Antibody Drug Conjugate, in Patients with Advanced, Progressive, Platinum-Resistant/-Refractory Epithelial Ovarian CancerDownload Presentation, CLICK HERE
Jefferies Virtual Healthcare Conference 2021 – Presentation
Webcast, Jun 2, 2021 at 4:30pm EST Download Presentation, Click Here
Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany
SOUTH SAN FRANCISCO, Calif., June 1, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – STRO-002 – Abstract
To view the abstract on ASCO, click here
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021
Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months One patient achieved a CR and nine patients achieved a PR, of which four were confirmed PRs. Median duration of response on the five confirmed...
Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 14, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones
- Additional follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021; enrollment for the dose-expansion is ongoing - Merck initiated IND-enabling toxicology studies for the first program under the cytokine derivatives collaboration...
7th Annual Truist Securities Life Sciences Summit – Presentation
Webcast, Click Here Download Presentation, Click Here
Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., April 20, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...
20th Annual Needham Virtual Healthcare Conference – Presentation
Webcast, Click Here Download Presentation, Click Here